# Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

> **NCT04855136** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 21 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** BB2121
- **DRUG:** CC-220
- **DRUG:** BMS-986405

## Key facts

- **NCT ID:** NCT04855136
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-01
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855136, "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04855136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*